Aurobindo Pharma Ltd. announced that the US Food and Drug Administration (FDA) has classified its Unit II formulation manufacturing facility, operated by Eugia Pharma Specialities, as ‘Official Action Indicated’ (OAI) following an inspection. The inspection took place from April 25 to May 3, 2024, at the Bhiwadi facility in Alwar, Rajasthan. Implications of OAI Classification …